Conferences

Timely clinical updates, expert perspectives, and key data from major oncology conferences, focusing on emerging evidence and treatment advancements across tumor types.

ASCO GU

Browse all ASCO GU

ASCO GU

Bladder, Kidney, and Prostate Cancer Highlights From ASCO GU 2026

Petros Grivas, MD, PhD, Rahul Gosain, MD, MBA, Rohit Gosain, MD

ASCO GU

ASCO GU 2026: Key Updates in Bladder, Prostate, and Kidney Cancer

Charbel Matar, MD

ASCO GU

Positive Trials for Belzutifan in Earlier Treatment Lines for RCC

Michael Serzan, MD, Toni Choueiri, MD

ASCO GU

Community Takeaways From ASCO GU 2026

Regina Barragan-Carrillo, MD, Raji Shameem, MD

ASCO GI

Browse all ASCO GI

ASCO GI

Gastrointestinal Cancers: Biomarker-Driven Advances in CRC and NETs

Deepak Vadehra, DO

ASCO GI

The Uncertain Role of ctDNA in Colorectal Cancers

Lauren Laderman, MD, Udhayvir Singh Grewal, MD

ASCO GI

Updating Care Models for Patients With Early-Onset GI Cancer

Youssef Bouferraa, MD, Shruti Patel, MD

ASCO GI

FDA Update Reflects Need for Genetic Testing Prior to Capecitabine

Karen Merritt, Vimal Scott Kapoor, MD, BSc, MSc

ASH

Browse all ASH

ASH

AML and CML Highlights From ASH 2025

Jorge Cortes, MD, Rahul Gosain, MD, MBA, Rohit Gosain, MD

ASH

Bispecifics, BTK Inhibitors, and Immunotherapy Drive Lymphoma Advances

Julie Vose, MD, MBA, Rahul Gosain, MD, MBA, Rohit Gosain, MD

ASH

AQUILA, COBRA, TecLILLE, and MajesTEC-3 Trials Signal Shifts in Myeloma Management

Ben Derman, MD, Rahul Gosain, MD, MBA, Rohit Gosain, MD

ASH

Expert Insight on Emerging Strategies in Multiple Myeloma

Mehndi Dandwani, MD

SABCS

Browse all SABCS

SABCS

Adjuvant Carboplatin and PARP Inhibitor Combination Trials in TNBC

Rebecca Shatsky, MD, Rahul Gosain, MD, MBA, Rohit Gosain, MD

SABCS

4 Significant Trials for HER2+ Breast Cancer at SABCS 2025

Harold Burstein, MD, PhD, Rohit Gosain, MD, Rahul Gosain, MD, MBA

SABCS

HR+ Metastatic Breast Cancer Updates from SABCS 2025

Hope Rugo, MD, FASCO, Rahul Gosain, MD, MBA, Rohit Gosain, MD

SABCS

From ADCs to Oral SERDs: Practice-Changing Insights from SABCS 2025

Zunairah Shah, MD

ESMO

Browse all ESMO

ESMO

Revolutionizing Treatment for EGFR-Mutated NSCLC

Coral Olazagasti, MD

ESMO

ESMO 2025: Updates in the HR+ Metastatic Breast Cancer Landscape

Sarah Premji, MD, Karthik Giridhar, MD

ESMO

5 Updates From ESMO 2025 for Lung Cancer Oncologists

Rami Manochakian, MD, Rohit Gosain, MD, Rahul Gosain, MD, MBA

ESMO

ESMO 2025 Updates in Prostate Cancer: Advances in Radioligand, Genomic, and AR-Targeted Therapies

Michael Serzan, MD

WCLC

Browse all WCLC

WCLC

Dual Targeting: Iza-bren Shows Promising Early Results Across Solid Tumors

Samantha El Warrak, MBBS, Chinmay Jani, MD

WCLC

PALOMA-2: Subcutaneous Amivantamab Plus Lazertinib Delivers MARIPOSA-Level Efficacy with Improved Safety

Akshee Batra, MD, Chinmay Jani, MD

WCLC

DLL3-Targeted Antibody-Drug Conjugate Reignites Hope for Relapsed SCLC

Asad Rauf, MD, Chinmay Jani, MD, Aman Chauhan, MD

WCLC

Chemotherapy Plus Osimertinib Offers Overall Survival Benefit in EGFR-mutated NSCLC

Daniel Tuerff, MD, Chinmay Jani, MD, Estelamari Rodriguez, MD, MPH

ASCO

Browse all ASCO

ASCO

Preferred Sequencing of Treatment for Neuroendocrine Tumors

Deepak Vadehra, DO, Tanios Bekaii-Saab, MD

ASCO

Updates in Breast Cancer From ASCO 2025

Zunairah Shah, MD

ASCO

Thoracic Oncology in 2025: Evolving Standards and Practice-Changing Data From ASCO

Kriti Ahuja, MD

ASCO

Innovación dirigida: datopotamab deruxtecan en el tratamiento del cáncer de pulmón no microcítico avanzado

Coral Olazagasti, MD, Narjust Florez, MD, FASCO